Motion-Secondary: ROBERT ROSS et al VS. C.C. MOORE & CO. ENGINEERS

• 
• 
• 
• 
• 
• 
• 
• 

						
                                
Preview
                                NIA 94948-6169

(415) 898-1555

PO BOX 6169

ATTORNEYS AT LAW
222 RUSH LANDING ROAD .

BRAYTON@PURCELL LLP

NOVATO, CALI

CoM aA DH FF WN

10

ALAN R. BRAYTON, ESQ., S.B. #73685

DAVID R. DONADIO, ESQ., S.B. #154436

JENNIFER L. ALESIO, ESO., $.B. #258413 ELECTRONICALLY

BRAYTON®PURCELL LLP FILED
ttomeys at Law Superior Court of California,

222 Rush Landing Road County of San Francisco
.O. Box

Novato, California 94948-6169 APR 29 2013

Clerk of the Court
BY: VANESSA WU
Deputy Clerk

(415) 898-1555
Attorneys for Plaintiffs

SUPERIOR COURT OF CALIFORNIA
COUNTY OF SAN FRANCISCO

ASBESTOS
No. CGC-10-275731

DECLARATION OF JENNIFER L.
ALESIO IN SUPPORT OF PLAINTIFFS’
OPPOSITION TO ANDERSON, ROWE &
BUCKLEY, INC.’S MOTION FOR .
SUMMARY JUDGMENT .

ROBERT ROSS and JEAN ROSS,
Plaintiffs,

vs.

C.C. MOORE & CO, ENGINEERS;

Defendants as Reflected on Exhibit 1
attached to the Summary Complaint

NN ee tee el el?

herein; and DOES 1-8500.
Date: May 9, 2013

Time: 9:30 a.m.

Dept: .503, Hon. Teri L. Jackson
Trial Date: June 10, 2013

Action Filed: December 17, 2010

I, Jennifer L. Alesio, declare:

1. Tam an attomey duly licensed to practice before all courts in the State of California
and am an associate with the law firm of Brayton¢Purcell LLP, attorneys of record for
plaintiffs herein. 1 have personal knowledge of the facts stated herein, and if called as a
witness, could and would competently testify to their truth.

2. Attached hereto as Exhibit A is a true and correct copy of the Declaration of David
Schwartz, M.D. and Exhibits thereto.

3. Attached hereto as Exhibit B is a true and correct copy of the relevant excerpts of
Deposition of Robert Morgan, taken on Nov. 7, 2007, in the matter of Jersey Gray vs. Allis-
Chalmers, Corp. (SFSC No.274042)

K2njured\s 944M plaldeal le ARAB, 1
ARA re RR LAINTIFF” iPPOSITIGN TO ANDERSON,
PER AU eR ey RS MOTION POR UMAR UDGMEN TEE S OPPOSITION TOeo Oe YW DH RW N

10

4. Attached hereto as Exhibit C is a true and correct copy of the relevant excerpts Trial
Testimony of Robert Morgan in the Phillip Hoeffer, Jr. matter (SFSC No. 413073), Vol. 15,
Proceedings of November 24, 2003. ,

I declare under penalty of perjury under the laws of the State of California that the
foregoing is true and correct.

Executed this Zl day of April 2013, atyNovato, California.

_ Alesio \.

KNlsured 193 0Riptdedi ta ARLE wo 2.
DECLARATION OF JENNIFER CL, ALESTO IN SUPPORT OF PLAINTIFF'S OPPOSITION TO ANDERSON,
ROWE & BUCKLEY, INC.’S MOTION FOR SUMMARY JUDGMENTEXHIBIT A222 RUSH LANDING ROAD
PO BOX 6169
NOVATO, CALIFORNIA 94948-6169

BRAYTON*PURCELL LLP.
ATTORNEYS AT LAW

(445) 898-1555

ALAN R. BRAYTON, ESQ., S.B. #73685
DAVID R. DONADIO, ESQ., S.B. #154436
JENNIFER L. ALESIO, ESQ., S.B. #258413
BRAYTON*PURCELL LLP
Attorneys at Law
222 Rush Landing Road
P.O. Box 6169
Novato, California 94948
(41) 898-1555
Attorneys for Plaintiffs
SUPERIOR COURT OF CALIFORNIA
COUNTY OF SAN FRANCISCO

ROBERT ROSS and JEAN ROSS, ASBESTOS
No. CGC-10-275731
Plaintiffs,
DECLARATION OF DAVID A. SCHWARTZ,
vs. M.D.

C.C. MOORE & CO. ENGINEERS;
Defendants as Reflected on Exhibit 1
attached to the Summary Complaint

herein; and DOES 1-8500.

Date: May 7, 2013

Time: 9:30 a.m.

Dept: 503, Hon. Teri L. Jackson
Trial Date: June 10, 2013

Action Filed: December 17, 2010

NN ee ee ee ee

I, David A. Schwartz, M.D., declare as follows:

1. Lam nota party to the above-referenced action. I have personal knowledge of the
facts set forth in this declaration, and if called upon as a witness, I could and would competently
testify as to their truth.

2. Lam a physician, currently employed by the University of Colorado as a Professor of
Medicine, Immunology, and Pediatrics, and serving as a Chair of the Department of Medicine at
the University of Colorado, I graduated from medical school in 1979, and I have been board
certified in medicine since 1984, in occupational medicine since 1986, and in pulmonary
medicine since 1988. A copy of my Curriculum Vitae, which includes a list of my publications
and grant support, is attached to this Declaration as Exhibit }.
tit

K Mnjured\19349\pldidecl schwartz. doo 1 ILA
DECLARATION OF DAVID A. SCHWARTZ, M.D.3. Lattended the University of Rochester, and received a Bachelor of Arts degree with
Honors in Biology in 1974. I then attended the University of California, San Diego, School of
Medicine and obtained my medical degree in 1979. Following medical school, in the summer of
1979, | took an 8-week course in tropical medicine at the Walter Reed Army Institute of
Research. The National Science Foundation supported me as a Public Service Science Resident
in population-based research until June of 1980. Between July 1980 and June 1984, I was an
intern, resident and chief resident in internal medicine at Boston City Hospital. J then became an
occupational medicine resident at Harvard School of Public Health and took courses in
epidemiology, occupational medicine, and industrial hygiene. 1 received a Master’s degree in
Public Health (MPH) in 1985 and joined the Robert Wood Johnson Clinical Scholars Program at
the University of Washington that allowed me to acquire research skills, complete my
occupational medicine residency, and start/complete a fellowship in pulmonary medicine. | was
recruited to direct the clinical program in occupational medicine at the University of Iowa in
1988 and was appointed Assistant Professor of Medicine in the Pulmonary Division in the
Department of Medicine. During that time, I collaborated with Drs. James Merchant and Gary
Hunninghake and focused my clinical and research efforts on understanding the environmental
and genetic determinants of pulmonary fibrosis and asthma. In 2000, I was recruited to Duke
University to direct the Division of Pulmonary and Critical Care Medicine. During that time, I
developed three NIH support programs in environmental health (environmental genomics,
environmental asthma, and an environmental health sciences research center). In 2005, I was
recruited to direct the National Institute of Environmental Health Sciences and the National
Toxicology Program and developed the Genes, Environment, and Health Initiative, and the NTH
Program in Epigenomics. In 2008, I was recruited to the National Jewish Center and developed
the Center for Genes, Environment, and Health where [ am currently serving as Provost. I have
co-authored 178 joumal articles, 68 editorials, and 52 book chapters. A number of these articles
have focused on asbestos-related lung disease. I have served on a number of journal editorial
boards (Am. J. Resp. Crit. Care Med and Am, J. Resp, Cell Mol Biol.), numerous grant review

committees, and am a member of the American Society for Clinical Investigation and

K Alnjured\}9349\pldidect schwartz.doc 2 JLA
DECLARATION OF DAVID A. SCHWARTZ, M.D,Association of American Physicians. In addition, I am the recipient of the 2003 American
Thoracic Society Scientific Accomplishment Award.

4. Since the late 1980s, I have participated in the diagnosis of approximately several
hundred cases of asbestos-induced lung disease that originated at the University of Iowa, Duke
University, or National Jewish Health where I am Professor of Medicine, Pediatrics, and
Immunology and Director of the Center for Genes, Environment, and Health. I have also seen
several hundred cases referred to me by other physicians or lawyers representing patients with
this disease. During the course of my career, I have kept abreast of the scientific and medical
literature regarding the diagnosis and causation of asbestos induced lung disease and asbestos-
induced cancers.

5. Over the past 20 years, I have clinically evaluated at least 2,000 patients with asbestos
related disease to determine the type of disease, to determine the relationship of that disease to
asbestos exposure, and to evaluate their exposure to asbestos.

6. [have been qualified to testify on the issue of diagnosis and causation in a number of
states including, but not limited to, North Carolina; South Carolina, Texas, Florida, Colorado,
California, and New York.

7. As I stated in my report of April 23, 2011, a true and correct copy attached hereto as
Exhibit 2, and my report dated December 28, 2010, a true and correct copy which is attached
hereto as Exhibit 3, having reviewed medical records from the plaintiff, Robert Ross, including
his pathology and radiology reports, and including pulmonologist Alvin J. Schonfeld, M.D.’s
report dated September 16, 2009. I conclude that Mr. Ross has asbestosis, as well as has
developed colon cancer which was in part caused due to his exposure to asbestos. Additionally,
people, such as Mr. Ross, with asbestos exposure with an additional history of tobacco exposure,
have a significantly higher incidence of cancer complications than with either asbestos or
tobacco exposure alone, as the combined increased risk of these two carcinogens is

multiplicative.
8. It is my opinion that every exposure to asbestos above background level contributed to

cause Mr. Ross’s asbestosis and colon cancer because it is well understood that asbestos related

KAinjured\19349\pididect schwartz.doc 3 JLA
DECLARATION OF DAVID A. SCHWARTZ, M.D.YI Dw B® WwW

diseases are dose-response related diseases and it is impossible to show exactly which exposures
to asbestos caused the disease. Asbestos fibers are complete human carcinogens. Every asbestos
fiber that comes into contact with a cell in the respiratory system or gastrointestinal system may,
ona more likely than not basis, elicit a physiological response from the body. The body has a
limited ability to deal with this exposure burden. Some of the fibers will stimulate removal
mechanisms and eventually be removed from the body. Any fiber contacting a cell may cause
genetic damage, may induce inflammatory reactions, or may cause other biochemical reactions,
including those which lead to the development of asbestosis and colon cancer. After accounting
for sufficient latency, these diseases result from cumulative exposure to asbestos. In individuals
who develop these diseases, such as Mr. Ross, every occupational or para-occupational exposure
to asbestos plays:a role in causing the disease.

9. T also reviewed the Declaration of Robert Morgan (“Morgan Decl.”) and Khalil
Sheibani, M.D. (“Sheibani Decl.”) attached in support of defendant’s Motion for Summary
Judgment in this case. Dr. Morgan attested that there is there is no causal relationship between
that the inhalation or ingestion of asbestos is a contributing factor in the development, or even
tisk factor for the development, of colon cancer. Morgan Decl. at §5. However, this is an
inaccurate conclusion that is not supported by the breadth of scientific literature on the topic
(beyond that which Dr. Morgan has evidently been paid to generate), For the reasons stated in
my declaration, I therefore also disagree with Dr. Morgan’s opinion there has been established
no causal relationship between asbestos exposure and colon cancer. Morgan Decl. at 95.

Dr. Sheibani concludes that based upon the absence of asbestos bodies in the limited colon tissue

that he was sent, that the colon cancer cannot be caused by asbestos exposure. Sheibani Decl. at

95-6. Here again, though I have no quarrel with his pathologic finding, his conclusion
regarding causation is not supported by the medical literature on the topic and does not even
correctly represent the criteria for establishing the link between asbestos exposure and lung
cancer from which Dr. Sheibani then extrapolates his conclusions about colon cancer. | note that
Dr. Sheibani does not cite to a single article or book chapter concerning the relationship between

asbestos and colon cancers in his declaration. Based on my above-mentioned experience,

KMinjured\19349\pid\decl schwartz.doc 4 JLA

DECLARATION OF DAVID A. SCHWARTZ, M.D.Cm WB DW BR YB Dm

o

11

training, and historical review, there are various articles that I have studied regarding the
association between asbestos exposure and colon cancer. A true and correct copy of the
Annotated Bibliography of Colon Cancer Articles is attached as Exhibit 4. Each and every one
of these peer reviewed articles in the attached Annotated Bibliography of Colon Cancer Articles
is independently a basis for my conclusion that it is generally accepted in the medical community
that exposure to asbestos can and does cause asbestos induced cancers of the G-I track, including
Mr. Ross’s asbestos induced colon cancer.

10. Based on my own evaluation of medical records, pathology and radiology reports in

this case, my own training, education, and experience, and the references also cited above, I

conclude exposure to asbestos contributed to cause Mr. Ross’s colon cancer and that every
occupational exposure to asbestos, above background, given sufficient minimum latency, was a
substantial contributing factor to both Mr. Ross’s asbestosis and his colon cancer, this exposure
was continuous, above background levels and substantial.

11. All my opinions expressed herein are to a reasonable degree of scientific certainty.

I declare under penalty of perjury under the laws of the United States of America and the
State of California that the foregoing is true and correct.

Executed on April 23" . 2013, at Denver, Colorado.

DVO

David A. Schwartz, M.D.

C\Users\Neese1.\AppData\Lacal\Microsof\Windows\Temporary Internet Files\Content Qutlogk\KT1 DXH78\deel schwartz.doc Sita
DECLARATION OF DAVID A. SCHWARTZ, MD.EXHIBIT 1Name:

Home Address:

Office Address:

Social:

CURRICULUM VITAE

David A. Schwartz

110 S. Jackson Street
Denver, CO 80209

5915 St. Mary's Road
Hillsborough, NC 27278
(919) 471-1253

National Jewish Health

1400 Jackson Street

Smith Building; A648

Denver, CO-80206

Telephone (303) 398-1903

Fax (303) 270-2136

E-Mail: schwartzd@njhealth.org

University of Colorado, Denver
Department of Medicine

12631 East 17° Avenue, B178
Aurora, CO 80045

Telephone (303) 724-1783
Fax (303) 724-1799

E-Mail: david. schwartz@ucdenver.edu

Born: March 3, 1953
Flushing, New York

Education and Medical Education:

1971-1974

1975-1979

1979

1979-1980

1980-1983

1983-1984

1984-1985

1985-1987

University of Rochester
College of Arts and Sciences
Rochester, New York

University of California, San Diego
School of Medicine
La Jolla, California

Walter Reed Army Institute
of Research
Tropical Medicine Training

Public Service Science Resident
National Science Foundation

Boston City Hospitat
Boston, Massachusetts

Boston City Hospital
Boston, Massachusetts.

Harvard School of Public Health
Boston, Massachusetts

Robert Wood Johnson Clinical
Scholars Program
University of Washington

B.A. (Biology)

M.D.

Medicine
intern and Resident

Chief Resident
in Medicine

NLP.H.
Occupational Medicine

Research FellowDavid A. Schwartz, M.D., M.P.H.

Curriculum Vitae
Page 2

1985-1988

1994-1995

Seattle, Washington

Division of Pulmonary and
Critical Care Medicine

University of Washington

Seattle, Washington

Sabbatical in laboratory of Dr. Jeffrey Murray

Academic Appointments:

1988-2000

1989-2000

1996-2000

4997-2000

2000-2005

2000-2005

2001-2005

2003-2005

2005-2008

2008-Present

Pulmonary Disease Division
Department of Internal Medicine
The University of lowa

lowa City, lowa

Veterans Administration Medical Center
fowa City, lowa

Department of Internal Medicine
The University of lowa
jowa City, lowa

College of Medicine
The University of lowa
lowa City, lowa

Duke University Medical Center
Durham, North Carolina

Veterans Administration Medical Center
Durham, North Carolina

Duke University Medical Center
Durham, North Carolina

Department of Medicine
Duke University Medical Center
Durham, North Carolina

National institute of Environmental Health
Sciences

National Toxicology Program

National institutes of Health

Research Triangle Park, North Carolina

National Jewish Health
Denver, Colorado

Pulmonary and Critical Care Fellow

Assistant, Associate, Full Professor
Director of Occupational Medicine

Staff Physician

Associate Chair for
Program Development

Director, Center for Environmental
Lung Disease

Professor of Medicine, Genetics, and
Environmental Sciences

Chief, Division of Pulmonary and Critical
Care Medicine

Director, Center for Environmental
Genomics, Institute for Genome Science
and Policy

Staff Physician
Walter Kempner Professor of Medicine

Vice Chair for Research

Director

Professer of Medicine, Pediatrics, and
Immunology

Director, Center for Genes, Environment,
and Heaith

Provost until 2014David A. Schwartz, M.D., M.P.H.
Curriculum Vitae

Page 3
2008-Present University of Colorado Denver Professor of Medicine and Immunology
School of Medicine Member, MSTP:
Denver, Colorado Member, Colorado Cancer Center
Member, Graduate School Faculty
Member, Human Medical Genetics and
Genomics Program
2011-Present University of Colorado Denver Chair, Department of Medicine
Schoo! of Medicine
Denver, Colorado
Certification:
1981 Diplomate, National Board of Medica! Examiners (#214457)
1984 Diplomate, American Board of internal Medicine (#095708)
41984 American Heart Association in Advanced Cardiac Life Suppart
1984 American College of Surgeons Certificate in Advanced Trauma Life Support
1986 Diplomate, American Board of Preventive Medicine, Occupational Medicine (#22231)
1988 Diplomate, American Board of internal Medicine Subspecialty
Board on Pulmonary Disease (#95708)
2005 Special Purpose Examination (#27421098)
Licensures:

Colorado (#47224); North Carolina (#20000691); South Carolina (#28514); Texas (#M0903);
Florida (#ME 107616)

Scholarly Societies:

1974
1979
1985

Phi Beta Kappa
National Science Foundation, Public Service Science Resident
Robert Wood Johnson Clinical Scholar

Professional Awards and Special Recognitions:

41991
1995
1999

Elected Member, American Federation of Clinical Research
Elected Member, American Society for Clinical Investigation (ASCI)
Elected Member, Association of the American Physicians (AAP)

2000-2011 Best Doctors in America

2003
2004

American Thoracic Society Lifetime Scientific Achievement Award
Kass Medal, University of Nebraska

2005-2008 Director, National Institute of Environmental Health Sciences, NIH
2005-2008 Director, National Toxicology Program, Department of Health and Human Services

2006

Jerome Flance Visiting Professor, Washington University

2006-2012 Castie Connolly American Top Doctor

2007
2007
2008
2008

Robert S. Harris Lecturer, Massachusetts Institute of Technology
Roger Mitchell Lecturer, Aspen Lung Conference

Nancy Middleton Smith Lecturer, University of Louisville

Alice Hamilton Lecturer, University of California, San Francisco

2009-Present Who's Who in America; Medicine, and Healthcare; Science and Engineering; and

2010
2010

American Politics
John Butier Endowed Lecture, University of Washington, Seattie
Borden Lecture, Northwestern University, Chicago

2010-Present Who's Who in the World

2014
2011
2012

Nobei Conference: Epigenetics in Clinical Medicine
Robert F. Johnston Lectureship Honoree, Drexel University
Fellow, American College of PhysiciansDavid A. Schwartz, M.D., M.P.H.
Curriculum Vitae

Page 4

Study Section, Editorial Boards, and Consultant Appointments:

1993-1997
1995-1999
4997-2000
1999-2003
2001-2005
1993-1996
1997-2006
2003-2008
2003-2008
1998-2000
1999-2005
2000-2005
2000-2005
2001-Present
2005-2008
2008
2008-Present
2009-2011
2010-Present

Member, ALA/ATS Research Grant Review Committee

Member, NIH Study Section GCRC, NCRR

Member and Chair, VA Merit Review Board - Puimonary Section

Member, NIH Environmental Health Science Review Committee

Member, NIH, NHLBI innovative Grant Program Review Committee

Member, Editorial Board, American Review of Respiratory Disease

Member, Editorial Board, American Journal of Medicine

Member, Editorial Board, Environmental Health Perspectives

Member, Editorial Board, American Journal of Respiratory Cell and Molecular Biology
Scientific Consultant to Biogen Corporation

Scientific Consultant to Eisai Corporation

Scientific Consultant to InterMune Corporation

Member, Duke Comprehensive Cancer Center

External Advisor, Thomas L. Petty Aspen Lung Conference

Chair, Transatlantic Ainway Conference Planning Committee

Chair, Helmholtz Center in Environmental Health

Associate Editor, American Journal of Respiratory Ceil and Molecular Biology
Member, Tobacco Related Disease Research Program Study Section

Steering Committee, Canine Lifetine Health Project, Morris Anima} Foundation

Organizations and Participation:

American Federation for Clinical Research
American Society for Ciinical Investigation (ASCI)
Association of American Physicians (AAP)
American Society of Human Genetics
American Public Health Association
Society of General Internal Medicine
American Thoracic Society
4993-1997 Member, ALA/ATS Research Grant Review Cammittee

1994

Member, ATS Planning Committee

1994-1999 Member and Chair, ATS Health Care Policy Committee

1996
1998
2000

Co-Chair, Health Care Policy Task Force
Member, ATS Nomination Committee
Chair, ATS Government Relations Committee

2001-2004 Member, ATS Scientific Advisory Committee
2002-2005 Member, ATS Publications Policy Committee
2002-2005 Chair, ATS Planning Committee

Area of Research:

« Genetics and Genomics of Pulmonary Fibrosis
« Gene Discovery in Innate Immunity
« Epigenetics of Environmental Lung Disease

Grant Support:
Title Period Total Direct Funding
Active:
NIH-NHLBI: RO1-HL095393 09/24/08-07/31/13 $2,000,000

Genomic Signatures for idiopathic
Interstitial Pneumonia
Principal investigator: SchwartzDavid A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 5

NIH-NHLBI: RO1-HL097163
GWAS in Fibrosing Interstitiat Lung Disease
Principal Investigator: Schwartz

NIH-NHLBI: RO1-HL 101251
Asthma: An Epidemic Caused by Epigenetics?
Multi-Principal Investigator: Schwartz

VA-Merit: 1101BX001534
Genetic and Epigenetic Changes in MUC5B
and Fibrosing Interstitial Lung Disease
Principal Investigator: Schwartz

NIH-NIERS: PO1-ES18181
Determinants of Environmental Airway Disease
in Children
Principal investigator: Schwartz
Project 3 Co-Leader: Schwartz

NIH-NHLBI: P01-HL092870
Mechanisms of Familial Pulmonary Fibrosis.

Gene and Environment Interactions in Pulmonary .

Fibrosis
Principal investigator: Blackwell
Project Director: Schwartz

NIH-NIAID: NO1-Ai90052
Inner City Asthma Consortium
The Role of Epigenetics in Inner City Asthma
Principal Investigator: Busse
Project Director: Schwartz

NIH-NCRR: $10-RRO31832
Supercomputer Linux Cluster for Genomics
and Proteomics
Principal Investigator: Schwartz

Pending:

NIH-NHLBE R24-HL110898
Lung Genomics Resource Central: A Resource
for Pulmonary Disease
Principal Investigator: Schwartz

NIH-NHGRI: U01-HG007284
Integrating Molecular Profiling into
Colorectal Cancer Care
Principal Investigator: Schwartz

Previous:
NIH-NHLBI: RC2-HL101715
Lung Genomics Research Consortium
Multi-Principal Investigator: Schwartz.

NIH-NHLBI: RC1-HLO99571
Peripheral Blood Biomarkers for Idiopathic

07/01/09-06/30/14
07/01/09-06/30/14

04/01/12-03/31/16

08/30/09-09/29/1 4

01/01/10-12/31/15

09/30/09-9/29/14

04/01/11-02/14/13

40/04/14 2-09/30/17

04/01/43-03/31/17

09/30/09-09/29/12

09/30/09-09/29/12

$5,623,923

$2,559,813

$650,000

$4,997,747

$2,473,497
(Schwartz project)

$2,465,777

$598,964

$7,500,000

$3,500,000

$12,000,000

$1,000,000David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 6

interstitial Pheumonia
Multi-Principal Investigator: Schwartz

NIH-NICHD: RC1-HD063508 09/30/09-09/29/12
Antenatal Dietary Supplementation is a Risk
Factor for Infant Atopy through Epigenetics
Multi-Principa! Investigator: Schwartz

NIH-NIEHS: 1-201-ES101945-01 5/23/05-5/22/08
The Genetic and Biological Determinants
of Environmental Airway Disease
Principal Investigator: Schwartz

NIH-NIEHS;: 1-201-ES101946-01 §/23/05-5/22/08
The Genetic Determinants of Innate Immunity
and Host Defense
Principal Investigator: Schwartz

NIH-NIEHS: 1-Z01-ES101947 . 5/23/05-5/22/08
The Genetic Determinants of Interstitial Lung Disease
Principal Investigator: Schwartz

NIH-NIEHS: U19. Center for 9/30/01-9/29/06
Environmental Genomics
Principal Investigator: Schwartz.

NIH-NIEHS: P01. PPG The Genetics and 42/1103-1 1/30/08
Pathogenesis of Environmental Asthma
Principal Investigator: Schwartz
Project 1: PI Schwartz

NIH-NIAID: R21. Gene Susceptibility to 9/30/04-9/29/08
F. Tularensis
Ca-investigator: Schwartz

NIH-NIEHS: P30..EHSRC ~ Center for Comparative 4/1104-3/31/08
Biology of Vulnerable Populations
Principal investigator: Schwartz

NIH-NIEHS: RO1. Biological Determinants of 9/1/95-8/3 1/06
Environmental Airway Injury
Principal investigator: Schwartz

NIH-NIEHS: K23 ~ TLR4 and Environmental Asthma 9/30/01-9/29/06
Principal investigator: John Sundy
Mentor: Schwartz

NIH-NHLBI: F32 ~The Genetics of Environmental 1/31/06-1/30/08
Airway Disease
Principal Investigator: Jaspal Singh
Co-Mentor: Schwartz

NIH-NHLBI: U01. A Linkage Study in Familial 9/29/00-9/28/05
Pulmonary Fibrosis
Principal Investigator: Schwartz

VA Merit. Positional Cloning of Novel Genes Involved = 1/1/03-12/31/08

$1,000,000

$600,000

$600,000

$600,000

$7,559,614

$7,200,000

$200,000

$4,004,000

$1,500,000

$500,000

$112,888

$3,457,673

$733,000David A. Schwartz, M.D., M.P.H.
Curriculum Vitae _
Page 7

In Innate Immunity
Principal investigator: Schwartz

NIH-NHLBI: U01: Mouse Modeis of Heart, Lung and

Blood Disease
Principal Investigator: Peters
Lung Core: Schwartz

NIH-NHLBI: Interdisciplinary Training Program
Grant in Lung Disease (132)
Principal Investigator: Schwartz

GSK Fellowship Award

Innate Immunity and Environmental Airway Disease

Principal Investigator: John Hollingsworth
Mentor: Schwartz

VA Merit Review Entry Proposal (MREP)
The Role for beta-arrestin-2 in Regulating Lung
Inflammatory Disorders
Principal Investigator: Julia Walker
Mentor: Schwartz

NH: K12 Genomic Approach to Innate Immunity
To Aspergillus
Principal tnvestigator: Aimee Zaas
Mentor: Schwartz

NIH-NHLBI: Microarray Expression Profiling
Of Rodent Models of Human Disease
Principal Investigator: Quackenbush
Lung Core: Schwartz

NIH-NIEHS: PPG in Environmental
Airway Disease
Principal Investigator: Schwartz
Project 2 Pi: Schwartz

VA Merit. Positional Cloning of the Lps
Response Gene.
Principal Investigator: Schwartz

NIH-NHLBi: RO1. Host Determinants of
Organic Dust-Induced Airway Disease
Principal investigator: Schwartz

CDC. Persian Gulf Research Project
Principal Investigator. Schwartz

NIH-NIEHS: Environmental Health Science
Research Center
immunogenetics Facility Director: Schwartz
Pulmonary Biology Core Director: Schwartz
Co-Principal Investigator: Schwartz

Short-term Training: Students in Health
Professional Schools

9/30/00-9/29/08

7/1104-8/30/09

7/4103-6/30/04

211104-1131/07

7/1103-6/30/05

9/30/00-9/29/04

9/1/98-8/31/03

9/1/97-8/3 1/02

12/1/98-7 1/30/02

12/1/94-4/30/00

4/1/96-3/31/01

5/1/00-4/30/05

$934,003

$2,237,579

$40,000

$385,178

$130,808

$384,253

$5,148,708

$500,000

$758,114

$3,500,000

$4,500,000

$842,840David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 8

Principal investigator: Schwartz

NIH-K08: Neutrophil Recruitment in
In LPS-induced Airway Disease
Principal investigator: Klekamp

NiH-K08: Genetic Determinants of
Pulmonary Fibrosis
Principal Investigator: Willis
Mentor: Schwartz

NiH-K08: Genetic Susceptibility to Inhaled
Lipopolysaccharide
Principal investigator: Cowden
Mentor: Schwartz

NIH-NIEHS: RO1. Grain Dust, Endotoxin, and
Airflow Obstruction
Principal Investigator: Schwartz

NIH-NHLBI: SCOR for Occupational and
Immunologic Lung Disease.
Project |: Determinants of the Disease
Activity and Prognosis for Interstitial
Lung Disease.
Principal Investigator: Schwartz

NiH-NHLBI: SCOR for Occupational and
Immunologic Lung Disease.
Clinical Core.
Principal Investigator: Schwartz.

Cystic Fibrosis Pilot Feasibility Study
Principal Investigator: Schwartz

NIH-NIOSH: Agricultural Center. Biomarkers
in Grain Dust-induced Airway Disease.
Principal investigator: Schwartz

NIH-NIEHS: CIA. The Epidemiotcgy of Vegetable

Dust-Induced Airway Disease.
Principal Investigator: Schwartz

VA-Merit. Grain Dust-induced Airway
Disease: A Longitudinal Study.
Principal Investigator: Schwartz

Asbestos Victims Special Fund Trust.
A Reliable and Valid Radiographic
Approach to Quantify Asbestos-
induced Lung Disease
Principat Investigator: Schwartz

NIH-NIOSH SERCA, Asbestos-Induced Pleural

Fibrosis and Lung Restriction.
Principal Investigator: Schwartz

7/1100-6/30/05

7/1/00-6/30/05

THAI99-8/30/04

9/01/93-B/31/98.

12/01 /91-1 1/30/96

42104/91-11/30/96

9/1/95-8/31/96

40/04/90-9/30/95

4/01/90-3/31/95

4/01/90-3/31/95,

1101/92-6/30/93

7/01/90-6/30/93

$513,000

$540,000

$540,000

$715,176

$343,288

$2,410,888

$40,000

$506,011

$300,000

$357,341

$140,741

$150,000David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 9

NIH-NIEHS: Environmental Health Sciences 9/29/90-3/31/96 $342,707
Core Center Grant.
Director Pulmonary Biology
Research Core: Schwartz
Principal investigator: Merchant

NIH-NHLBI: P50-HL094917 12/01/08-11/30/11 $12,374,368
Host Defense Mechanisms in Chronic Lung Disease
Principal Investigator: Wright
Co-Investigator: Schwartz

NIH-NIAID: RO1-Al068804. 10/01/06-9/30/11 $2,066,365
Host Susceptibility in Staph aureus bacteremia
Principal Investigator: Fowler
Co-Investigator: Schwartz

NIH-NHLBI: K23 — Innate Immunity in Lung THN2-6/30/07 $500,000
Transplantation induced Bronchiolitis Obliterans. .
Principal Investigator: Scott Palmer
Mentor: Schwartz

NIH-NIEHS: K08 — Innate Immune Response to 2/1704-1/31/09 $500,000
Environmental Endotoxin
Principal Investigator: John Hollingsworth
Mentor: Schwartz

NIH-NIAID: KO8 ~ Genetic Determinants of A. 7/15/05-5/31/09 $471,576
Fumigatus Susceptibility
Principal investigator: Aimee Zaas
Co-Mentor: Schwartz
Patents Awarded:

"Use of nucleic acids containing unmethylated CpG dinucleotide int the treatment of LPS-associated
disorders" US Patent application serial no: 6,214,806B1; awarded April 2001

“Variant TLR4 nucleic acid and uses thereof” US Patent application serial no: 6,740,487 B1; awarded May
25, 2004

“Toll-like receptor 4 mutations” US Patent application serial no: 10,316,191; awarded July § 2005.

“Polymorphism in Tryptophan Hydroxylase-2 Controls Brain Serotonin Synthesis” US Patent application
serial no: 7585627; awarded September 8, 2009

“Variant TLR4 nucleic acid and uses thereof’ US Patent serial no: 7,785,794; awarded August 31, 2010
Patents Pending:

“Identification of a novel protein target for the treatment of (allergic) asthma”. US Patent application serial
no:

“Polymorphic plasminogen genes and uses thereof". US Patent application serial na: 11/108,459.

“Identification and diagnosis of pulmonary fibrosis using mucin genes and related methods and
compositions”. US Patent application serial no: 60/992,079.David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 10

“Peripheral Bload Biomarkers for Idiopathic interstitial Pneumonia and Methods of Use”. US Patent
application serial no: 61/248,505.

“Methods and Compositions for Risk Prediction, Diagnosis, Prognosis, and Treatment of Pulmonary
Disorders”. US Patent application serial no: 61/298,473.,

“Molecular Phenotyping of Idiopathic Interstitial Pneumonia Identifies Two Subtypes of Idopathic Pulmonary
Firbrosis”, US Patent application serial no: 61/666,233.
Original Manuscripts:

1. Patterson B, Craven D, Schwartz DA, Nardel! EA, Kasmer J, Noble J. Occupational hazards to
hospital personnel. Ann Intern Med 1985; 102:658-680.

2. Schwartz DA, Newsum L, Heifetz RM. Parental occupation and birth outcome in an agricultural
community. Scand J Work Environ Health 1986; 12:51-54.

3. Schwartz DA, Reilly P. The choice not to be resuscitated. J Am Geriatr Soc 1986; 34:807-811.
4. Schwartz DA. Acute inhalational injury. State Art Rev Occup Med 1987; 2:297-318.

5. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for airflow
obstruction in recipients of bone marrow transplants. Ann Intern Med 1987; 107:648-656.

6. Schwartz DA, Baker EL. Respiratory iliness in the construction industry: Airflow obstruction among ©
painters. Chest 1988; 93:134-137,

7. Schwartz DA, Rosenstock L, Barnhart S, inui T. Screening for occupational disease among workers
in a high-risk trade: examination of cost, yield, and potential for increased efficiency. Am J Industrial
Med 1988; 13:241-252.

8. Crawford SW, Schwartz DA, Peterson FB, Clark JG. Mechanical ventilation after marrow
transplantation: Risk factors and clinical outcomes, Am Rev Respir Dis 1988; 137:682-687.

9. Schwartz DA, LoGerfo JP. Congenital limb reduction defects in the agricultural setting. Am J Public
Hith 1988; 78:654-659.

10. Schwartz DA, Vaughan TL, Heyer NJ, Koepsell TD, Lyon JL, Swanson GM, Weiss NS. B celi
neoplasms and occupational asbestos exposure. Am J Industrial Med 1988; 14:661-671.

44. Schwartz DA, Rosenstock L, Clark JG. Monocyte-derived growth factors in asbestos-induced
interstitial fibrosis. Environ Res 1989; 49:283-294.

42. Schwartz DA, Smith DD, Lakshminarayan S. The pulmonary sequelae associated with accidental
inhalation of chlorine gas. Chest 1990; 97:820-825.

13. Schwartz DA, Fuortes LJ, Galvin JR, Schmidt LE, Leistikow BN, LaMarte FP, Merchant JA. Asbestos-
induced pleural fibrosis and impaired lung function. Am Rev Respir Dis 1990; 141:321-326.

44. Schwartz DA, Galvin JR, Dayton.CS, Stanford W, Merchant JA, Hunninghake GW. Determinants of
restrictive lung function in asbestos-induced pleural fibrosis. J Appi Physio! 1990; 68:1932-1937.

15, Rosenstock L, Daniell W, Barnhart S, Schwartz D, Demers PA. Chronic neuropsychological sequelae
of occupational exposure to organophosphate insecticides. Am J Ind Med 1990; 18:321-325.David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 11

16.

17.
18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30,

31.

Kern JA, Schwartz DA, Nordberg JA, Weiner DB, Greene MI, Torney L, Robinson RA. pi85neu
expression in human jung ademocarcinomas predicted shortened survival. Cancer Res 1990;
50:5184-5191,

Schwartz DA, New developments in asbestos-induced pleural disease. Chest 1991; 99:191-198.

Schwartz DA, Wakefield DS, Fieselmann JF, Berger-Wesley M, Zeitler R. The occupational history in
the primary care setting. Am J Med 1991; 90:315-319.

Peterson MW, Geist LJ, Schwartz DA, Konicek S, Moseley PL. Outcome after cardiopulmonary
resuscitation in a medical intensive care unit. Chest 1991; 100:168-174.

Schwartz DA, Galvin JR, Merchant RK, Dayton CS, Merchant JA, Hunninghake GW. The clinical
utility and reliability of asbestos bodies in bronchoalveolar fluid, Am Rev Respir Dis 1991; 144:684-
688.

Schwartz DA, Merchant RK, Helmers.RA, Gilbert SR, Dayton CS, Hunninghake GW. The influence of
cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis
1991; 144:504-506.

Landas SK, Schwartz DA. Mica-associated pulmonary interstitial fibrosis: A case report. Am Rev
Respir Dis 1991; 144:718-721.

Schwartz DA, Heimers RA, Dayton CS, Merchant RK, Hunninghake GW. Determinants of
branchoaiveolar lavage cattularity in idiopathic pulmonary fibrosis. J App! Physiol 1991; 71(5):1688-
1693.

Schmidt LE, Thorne PS, Watt JL, Schwartz DA. Is an abbreviated bronchial challenge with Fistamine
valid? Chest 1992; 101:141-145.

Broderick A, Fuortes LJ, Merchant JA, Galvin JR, Schwartz DA. Pleural determinants of restrictive
jung function and respiratory symptoms in an asbestos-exposed population. Chest 1992; 101:684-
691,

Schwartz DA, Galvin JR, Merchant RK, Dayton CS, Merchant JA, Hunninghake GW. Influence of
cigarette smoking on bronchoalveolar lavage cellularity in asbestos-induced lung disease. Am Rev
Respir Dis 1992; 145:400-405.

Schwartz DA, Landas SK, Burmeister LF, Hunninghake GW, Merchant JA. Airway injury in swine
confinement workers. Ann Intern Med 1992; 116:630-635.

Merchant RK, Schwartz DA, Helmers RA, Dayton CS, Hunninghake GW. Bronchoalveolar lavage
cellularity: The distribution in normal volunteers. Am Rev Respir Dis 1992; 146:448-453.

Dayton CS, Schwartz DA, Helmers RA, Pueringer RJ, Gilbert SR, Merchant RK, Hunninghake GW.
Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy - implications for
further studies. Chest 1993; 103:69-73.

Pueringer RJ, Schwartz DA, Dayton CS, Gilbert SR, Hunninghake GW. The relationship between
alveolar macrophage TNF, IL-1, and PGE; release, alveolitis, and disease severity in sarcoidosis.
Chest 1993; 103:832-838.

Schwartz DA, Galvin JR, Yagla SJ, Speakman SB, Merchant JA, Hunninghake GW. Restrictive tung
function and asbestos-induced pleural fibrosis: A quantitative approach. J Clin Invest 1993; 91:2685-
2692.David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 12

32.

33.

34,

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

Shih JF, Hunninghake GW, Goeken NE, Galvin JR, Merchant JA, Schwartz DA. The relationship
between HLA-A, B, DQ, and DR antigens and asbestos-induced lung disease. Chest 1993; 104:26-
34.

Kline JN, Schwartz DA, Monick MM, Ficerchinger CS, Hunninghake GW. Relative release of
interleukin-1B and interleukin-1 receptor antagonist by alveolar macrophages: a study in asbestos-
induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis. Chest 1993; 104:47-53.

Schwartz DA, Galvin JR, Frees Ki, Dayton CS, Burmeister LF, Merchant JA, Hunninghake GW.
Clinical relevance of cellular mediators of inflammation in workers exposed to asbestos. Am Rev
Respir Dis 1993; 148:68-74.

Clapp WD, Thorne PS, Frees KL, Zhang X, Lux CR, Schwartz DA. The effects of inhatation of grain
dust extract and endotoxin on upper and lower airways. Chest 1993; 104:825-830.

Hartley PG, Galvin JR, Hunninghake GW, Merchant JA, Yagla SJ, Speakman SB, Schwariz DA. High
resolution CT-derived measures of lung densily are valid indexes of interstitial lung disease. J App
Physiol 1994; 76:271-277.

Schwartz DA, Van Fossen DS, Heimers RA, Dayton CS, Burmeister LF, Hunninghake GW.
Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994;
149:444-449.

Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, Dayton CS, Burmeister LF,
Hunninghake GW. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care
Med 1994; 149:450-454. me

Kern JA, Stebos R, Top B, Robinson R, Weiner D, Schwartz DA. C-ERBB-2 expression and codon 12
K-RAS mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J
Clin Invest 1994; 93:516-520.

Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R,
Schwartz DA. Qutcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149:893-
898.

Shih JF, Wilson JS, Broderick A, Watt JL, Galvin JR, Merchant JA, Schwartz DA. Asbestos-induced
pleural fibrosis and impaired exercise physiology. Chest 1994; 105:1370-1376.

Clapp WD, Becker S, Quay J, Watt JL, Thorne PS, Frees KL, Zhang X, Koren HS, Lux CR, Schwartz
DA. Grain dust-induced airflow obstruction and inflammation of the lower respiratory tract. Am J
Respir Crit Care Med 1994; 150:61 1-617.

Schwartz DA, Davis CS, Merchant JA, Bunn WB, Galvin JR, Van Fossen DS, Dayton CS,
Hunninghake GW. Longitudinal changes in lung function among asbestos-exposed workers. Am J
Respir Crit Care Med 1994; 150:1243-1249.

Schwartz, DA, Thorne PS, Jagielo PJ, White GE, Bleuer SA, Frees KL. Endotoxin responsiveness
and grain dust-induced inflammation in the lower respiratory tract. Am J Physiol: Lung Cell Mol
Physiol 1994; 267:L609-L617.

Schwartz DA, Donham KJ, Olenchock SA, Popendorf WJ, Van Fossen DS, Burmeister LF, Merchant
JA. Determinants of longitudinal changes in spirometric function among swine confinement operators
and farmers. Am J Respir Crit Care Med 1995; 151:47-53.

Dayton CS, Schwartz DA, Sprince NL, Yagia SJ, Davis CS, Koehnke RK, Furst DE, Hunninghake,
GW. Low dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Amer J
Respir Crit Care Med 1995; 151:1189-1193.David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 13

47.

48.

49.

50.

51.

52.

53.

Quinn TJ, Donham KJ, Merchant JA, Schwartz DA. Peak flow as a measure of airway dysfunction in
swine confinement operators. Chest 1995; 107:1303-1308.

Chan-Yeung M, Brooks S, Alberts M, Balmes JR, Barnhart S, Baxcom R, Bernstein L, Grammer LC,
Harber P, Malo J-L, Rose C, Schwartz DA, Tarlo SM, Utell MJ. ACCP Consensus Statement.
Assessment of asthma in the workplace. Chest 1995; 108:1084-1117.

Schwartz DA, Thorne PS, Yagia SJ, Burmeister LF, Olenchock SA, Watt JL, Quinn TJ. The role of
endotoxin in grain dust-induced lung disease. Am J Respir Crit Care Med 1995; 152:603-608.

dagielo PJ, Thorne PS, Kern JA, Quinn TJ, Schwartz DA. The role of endotoxin in grain dust-induced
inflammation in mice. Am J Physiol: Lung Cell Mo! Physiol 1996; 207:L1052-L1059.

Blaski CA, Frees KL, Watt JL, Quinn TJ, Yagla SJ, Thorne PS, Schwartz DA. Nasal lavage cellularity,
grain dust, and airflow obstruction. Chest 1996; 109:1086-92.

dagielo PJ, Thorne PS, Watt JL, Frees KL, Quinn TJ, Schwartz DA. Grain dust and endotoxin
inhalation produce similar inflammatory responses in normai subjects. Chest 1996; 110:263-270.

Blaski GA, Clapp WD, Thorne PS, Quinn TJ, Watt JL, Frees K, Yagla SJ, Schwartz DA. The role of
atopy in grain dust-induced airway disease. Am J Respir Crit Care Med 1996; 154:334-340.

. Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, Schwartz DA.

Rheumatoid-arthritis lung disease: Determinants of radiographic and physiologic abnormalities.

- Arthritis and Rheumatism 1996; 39:1711-1719.

55.

56.

57.

58.

59.

60.

61.

62.

63.

Schwartz DA, and The lowa Persian Gulf Study Group: Seif reported iiness and health status among
Gulf War veterans. A population-based study. JAMA 1997; 277:238-245.

Deetz OC, Jagielo Pu, Quinn Td, Thome PS, Bleuer SA, Schwartz DA. The kinetics of grain dust-
induced inflammation of the lower respiratory tract. Am J Respir Crit Care Med 1997; 155:254-259,

dagielo PJ, Watt JL, Quinn TJ, Knapp HR, Schwartz DA. Pentoxifylline does nat alter the response to
inhaled grain dust. Chest 1997; 111:1429-1435.

Coxson HO, Hogg JC, Mayo JR, Behzad H, Whittail KP, Schwartz DA, Hartley PG, Galvin JR, Wilson
JS, Hunninghake GW. Quantification of idiopathic pulmonary fibrosis using computed tomography
and histology. Am J Respir Crit Care Med 1997; 155:1649-1656.

Schwartz DA, Quinn TJ, Thorne PS, Yi AK, Krieg AM. CpG motifs in bacterial DNA cause
inflammation in the lower respiratory tract. J Clin Invest 1997; 100:68-73.

Saag KG, Cerhan JR, Kolljuri S, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid
arthritis severity. Ann Rheum Dis 1997; 56:463-469.

Peiffer-Schneider S, Schutte BC, Murray JC, Frees KL, Williamson K, Leysens NJ, Schwartz DA.
Exclusion of /fa and /fb as the Lps gene and mapping of three markers near the Lps locus.
Mammalian Genome 1997; 8:785-786.

Jagielo Pu, Quinn TJ, Qureshi N, Schwartz DA. Grain dust induced tung inflammation is reduced by
Rhodobacter spheroides diphosporyl lipid A, Am J Physiol (Lung Cell Mol Physiol) 1998; 274:L26-
131.

Trapp JF, Watt JL, Frees KL, Quinn TJ, Nonneman MW, Schwartz DA. The effect of glucocorticoids
on grain dust induced airway disease. Chest 1998; 113:505-513.David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 14

64,

65.

66.

67.

68.

69.

70.

71,

72.

73.

74,

75.

76.

77,

78.

Wohfford-Lenane CL, Deetz DC, Schwartz DA. Cytokine gene expression following inhalation of corn
dust. Am J Physiol: Lung Cell Mol Bio! 1999; 276:L736-L743,

Kline JN, Cowden JD, Hunninghake GW, Watt JL, Wohlford-Lenane CL, Powers LS, Jones MP,
Schwartz DA. Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Crit Care
Med 1999; 160:297-303.

Schwartz DA, Wohiford-Lenane CL, Quinn TJ, Krieg AM. Bacterial DNA or oligonucleotides
containing unmethylated CpG motifs can minimize LPS-induced inflammation in the lower respiratory
tract through an IL-12 dependent pathway. J Immunology 1999; 163:224-231. .

Black DW, Doebbeling BN, Voelker MD, Clarke WR, Woolson, RF, Barrett DH, Schwartz DA. Quality
of life and heaith services utilization in a population-based sample of military personnel reporting
multipfe chemical sensitivities. J Occup Environ Med 1999; 41:928-933.

Becker S, Clapp WD, Quay J, Frees KL, Koren HS, Schwartz DA. Compartmentalization of the
inflammatory response to inhaled grain dust. Am J Respir Crit Care Med 1999; 160:1309-1318.

Quinn TJ, Taylor S, Wohiford-Lenane CL, Schwartz. DA. IL-10 reduces grain dust-induced airway
inflammation and airway hyperreactivity. J App! Physiol 2000; 88:173-179.

Black DW, Doebbeling BN, Voelker MD, Clarke WR, Woolson RF, Barrett DH, Schwartz DA. Multiple
chemical sensitivity syndrome: symptom prevalence and risk factors in a military population. Arch
Intern Med 2000; 1.60:1169-1176.

Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA.
TLR4 mutation is associated with endotoxin hyporesponsiveness i in humans. Nature Genetics 2000; ~
25:187-194. .

Doebbeling BN, Clarke WR, Watson D, Torner JC, Woolson RF, Voelker MD, Barrett DH, Schwartz
DA. is there a Persian Gulf War syndrome? Evidence from a large population-based survey of
veterans and nondeployed controls. Am J Med 2000; 108(9): 695-704.

King TE, Costabel U, Cordier JF, DoPico GA, du Bois RM, Lynch D, Lynch JP, Myers J, Panos R,
Raghu G, Schwartz DA, Smith CM. Idiopathic pulmonary fibrosis: diagnosis and treatment.
Intemational consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.

Kline JN, Jagielo PJ, Watt JL, Schwartz DA. Bronchial hyperreactivity is associated with enhanced
grain dust-induced airflow obstruction. J App! Physiol 2000; 89(3): 1172-1178.

Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the Toll-like
receptor 2 gene and its potential association with staphylococcal infection. infect immun 2000; 68(141):
6398-6401.

Zwerling C, Torner JC, Clarke WR, Voelker MD, Doebbeling BN, Barrett DH, Merchant JA, Woolson
RF, Schwartz DA. Self-reported postwar injuries among Gulf War veterans. Public Health Rep 2000;
116(4):346-349.

George CS, Schwartz DA. The role of endotoxin in acute and chronic grain dust induced airway
disease. Relationships Between Acute and Chronic Effects of Air Pollution, edited by U. Mohr et at.
Washington, ILSi Press, 2000, p. 169-184.

Moreland JG, Fuhrman RM, Wohiford-Lenane CL, Quinn TJ, Benda E, Pruessner JA, Schwartz DA.
TNF-o. and IL-1B are fot essential to the inflammatory response in LPS induced airway disease. Am J
Physiol: Lung Cell Moi Biol 2001; 280(1):L173-L180.David A. Schwartz, M.D., M.P.H.
Curriculum Vitae
Page 15

79.

80.

81.

82.

83.

84,

85.

86.

87.

88.

89.

90.

91.

George CLS, Jin H, Wohlfard-Lenane CL, O’Neill ME, Phipps JC, O'Shaughnessy P, Kline JN, Thorne
PS, Schwartz DA. Endotoxin responsiveness and subchronic grain dust-induced airway disease. Am J
Physiol: Lung Cell Moi Bic! 2001; 280:L203-L213.

Schwartz DA, Christ WJ, Wohiford-Lenane CL. Inhibition of LPS induced airway hyperresponsiveness
and airway inflammation by LPS antagonists. Am J Physiol: Lung Cell Mol Physiol 2001; 280; L771-
L778.

Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, Heine H, Latz E, Monks BG, Schwartz DA,
Miyake K, Golenbock DT, Molecular genetic analysis of an endotoxin non-responder mutant ceil line:
a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med
2001; 194:79-88.

Hunninghake G, Zimmerman MB, Schwartz DA, King TE, Lynch J, Hegele R, Hogg J, Waldron J,
Colby T, Muller N, Lynch D, Galvin J, Gross 8, Toews G, Helmers R, Cooper JA, Baughman R,
Strange C, Millard M, Stutzman J. Utility of lung biopsy for the diagnosis of idiopathic puimonary
fibrosis. Am J Resp Crit Care Med 2001; 164:193-196.

Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR.
Biotechinques 2001; 31(1):22-24.

Lorenz E, Jones M, Wohiford-Lenane C, Meyer N, Frees KL, Arbour NC, Schwartz DA. Genes, other
than TLR4, are involved in the response to inhaled LPS. Am J Physiol: Lung Cell Mo! Physiol 2001;
281:L1106-1414.

Zeldin DC, Wohiford-Lenane C, Chulada P, Bradbury JA, Scarborough PE, Roggli V, Langenbach R,
Schwartz DA. Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice
exposed to bacterial lipopolysaccharide. Am J Respir Cell Biol 2001; 25:457-465.

Lorenz E, Schwartz DA, Martin PJ, Gooley T, Lin MT, Chien JW, Hansen JA, Clark JG. Association of
TLR-4 mutations and the risk for acute GVHD after HLA-matched sibling hematopoietic stem cell
transplantation. Bio! Blood Marrow Transplant 2001; 7:384-387.

Doebbeling BN, Jones MF, Hall DB, Clarke WR, Woolson RF, Torner JC, Burmeister LF, Snyders-
Crumiey TL, Barrett DH, Falter KH, Merchant JA, Nusser S, Anderson D, Schwartz DA.
Methodological issues in a population-based heaith survey of Gulf War veterans. J Clin Epidemio!
2002, 55(5):477-487.

Thomas AL, Lane K, Phillips lil J, Prince M, Markin C, Speer M, Schwartz DA, Gaddipati R, Marney A,
Johnson J, Haines J, Stahiman M, Loyd JE. Heterozygosity for a surfactant protein C gene mutation
associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one
kindred. Am J Resp Crit Care Med 2002; 165:1322-1328.

Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLRA receptor in patients
with Gram negative septic shock. Arch Int Med 2002; 162:1028-1032.

Voelker MD, Saag KG, Schwartz DA, Chrischilles E, Clarke WR, Woolson RF, Doebbeling BN.
Health-related quality of life among Gulf War era veterans